Arthur C. Theodore, MD

Associate Professor of Medicine

View CV

Education:

MD, Boston University

General field of research:

Systemic Sclerosis Interstitial Lung Disease

Affiliations other than medicine:

Evans Center for Interdisciplinary Biomedical Research

The Pulmonary Center

The Scleroderma Center in the Division of Rhematology

The Scleroderma Lung Study Investigators

Contact information:

Office
The Pulmonary Center, R3 7115 Albany St, Boston, MA 02118

Phone: (617)-638 8691

Fax: (617)-638 5298

atheodor@bu.edu

Keywords:

Systemic Sclerosis Scleroderma; Interstitial Lung Disease; Cyclophosphamide Mycophenolate

Summary of research interest:

Randomized, multicenter, double blinded comparison of mycophenolate compared to oral cyclophosphamide in the treatment of active systemic sclerosis interstitial lung disease

Recent publications:

Strange C, Bolster MB, Roth MD ,Silver RM, Theodore A, Goldin J,Clements P, Chung J, Elashoff RM,Suh R, Smith EA, Furst DE, Tashkin DP and the Scleroderma Lung Study Research Group. 2008. Bronchoalveolar Lavage and the Response to Cyclophosphamide in Scleroderma Interstitial Lung Disease.  American Journal of Respiratory & Critical Care Medicine; 177:91-8.

Tashkin DP, Elashoff R,  Clements PJ, Roth MD, Furst DE,. Silver RM, Goldin J, Arriola E, Strange C,. Bolster MB, Seibold JR,  Riley DR, Hsu  VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K,Connolly M, Golden J, Olman M,Fessler F, Rothfield N, Metersky M, Khanna D, Li N, and Li G .for the Scleroderma Lung Study (SLS) Research Group*. 2007.  Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease.  American Journal of Respiratory and Critical Care medicine;176:1026-1034.

Khanna D., Yan X., Tashkin DP., Furst DE., Elashoff R., Roth MD., Silver R., Strange C., Bolster M., Seibold JR., Riley DJ,. Hsu VM., Varga J., Schraufnagel DE., Theodore A,. Simms R,. Wise R., Wigley F., White B., Steen V., Read C., Mayes M., Parsley E., Mubarak K., Connolly MK., Golden J., Olman M., Fessler B., Rothfield N., Metersky M., Clements PJ., Scleroderma Lung Study Group. 2007.  Impact of oral cyclophosphmide on Health-related Quality of Life in Patients with active scleroderma lung disease.  Results from the Scleroderma Lung Study.  Arthritis & Rheumatism; 56:1676-1684.

Tashkin D., Elashoff R,  Clements PJ, Roth MD, Furst DE,. Silver RM, Goldin J, Arriola E, Strange C,. Bolster MB, Seibold JR,  Riley DR, Hsu  VM, Varga J, Schraufnagel D, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K,Connolly M, Golden J, Olman M,Fessler F, Rothfield N, Metersky M, Khanna D, Li N, and Li G. 2006. The Scleroderma Lung Study:  Oral Cyclophosphamide versus Placebo for the Treatment of  Scleroderma-Related Interstitial Lung Disease.  New England Journal of Medicine; 354(25); 2655-2666.

Technologies available for sharing upon request

Bronchoalveolar Lavage with Assessment of Cell Counts and Selective Cytokines